SITC 2021 | Correlation between cutaneous immune-related adverse events and OS with immune checkpoint inhibitors

Yevgeniy R. Semenov, MD, Massachusetts General Hospital, Boston, MA, discusses a study of 14,000 patients who received immune checkpoint inhibitors (ICIs), in which development of cutaneous immune-related adverse events was shown to be correlated with an improvement in overall survival (OS). There is currently little data on the cutaneous toxicity of ICIs. This study therefore raises interesting questions about how the development of these toxicities could be useful in determining how successfully patients are responding to immunotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.